Abstract: A method for detection of the presence and/or quantities of silver nanoparticles in a specimen is shown. The method includes the steps of a) providing a detection organism suspended in a medium, b) treating the detection organism with zinc ions thus effecting auto-fluorescence therefrom, and then measuring degree of fluorescence of the detection organism suspended medium, c) adding the specimen to the detection organism suspended medium, treating the detection organism therein with the specimen for a period of time, and measuring change of fluorescence of the detection organism-suspended medium over time, d) calculating amount of silver ions intracellularly dissolved from the silver nanoparticles and accumulated in the detection organism in view of the change of fluorescence, and e) extrapolating quantity of silver nanoparticles in the specimen in view of the change of fluorescence and the amount of the intracellularly dissolved silver ions.
Abstract: Provided is a method for alleviating, preventing or treating a neurodevelopmental disease, neurologic disease, or psychiatric disease, comprising administering to a subject in need thereof a composition including, as an active ingredient, vesicle derived from Micrococcus luteus, wherein the disease including Alzheimer's disease, Parkinson's disease, amyotropic lateral sclerosis, Huntington's disease, epilepsy, multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, diabetic neuropathy, autism spectrum disorder, attention deficit hyperactivity syndrome, major depressive disorder, bipolar disorder, anxiety disorders, schizophrenia, obsessive compulsive disorder, post-traumatic stress disorder, dissociative disorders, eating disorders, substance use disorder, and personality disorders occurring as a result of neurogenesis dysfunction or neuroinflammation.
Abstract: The present application provides methods, imaging agents and kits for determination of the distribution and expression levels of an immune checkpoint ligand (such as PD-L1 or a PD-L1 like ligand) in an individual having a disease or condition. Anti-PD-L1 antibody agents, and methods for treating diseases or disorders by administering anti-PD-L1 antibody agents are also provided.
Type:
Grant
Filed:
May 31, 2019
Date of Patent:
May 21, 2024
Assignee:
Tayu Huaxia Biotech Medical Group Co., Ltd.
Abstract: A population of human polygonal RPE cells is disclosed. At least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms. Methods of generating same are also disclosed.
Type:
Grant
Filed:
December 8, 2021
Date of Patent:
May 21, 2024
Assignee:
CELL CURE NEUROSCIENCES LTD.
Inventors:
Osnat Bohana-Kashtan, Lior Ann Rosenberg Belmaker, Ofer Wiser
Abstract: The present invention provides devices, and a method for preparing the devices, for measuring glucose concentration in a liquid sample. The devices are typically in the form of test strips. The test strips are printed with a reagent varnish comprising glucose oxidase, peroxidase, chromogen, and neutralizer. The chromogen in the reagent varnish changes color when the reagent varnish is exposed to glucose.
Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.
Type:
Grant
Filed:
May 10, 2019
Date of Patent:
April 30, 2024
Assignee:
Neuracle Science Co., Ltd.
Inventors:
Bongcheol Kim, Wonkyum Kim, Jeongwon Yoon, Junho Chung, Junyeong Jin, Eunhwoi You
Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.
Type:
Grant
Filed:
April 2, 2021
Date of Patent:
April 30, 2024
Assignee:
VISTERRA, INC.
Inventors:
Karthik Viswanathan, Kenneth Douglas Johnson, Obadiah Joseph Plante, James C. Delaney, Tyree J. Koch, Hamid Tissire, Andrew M. Wollacott, Boopathy Ramakrishnan
Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
May 23, 2023
Date of Patent:
April 30, 2024
Inventors:
Jens Hukelmann, Heiko Schuster, Ricarda Hannen, Christoph Schraeder, Jens Fritsche, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor
Abstract: The invention relates to an antibody which binds to chondroitin sulfate proteoglycan 5 (CSPG5) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.
Type:
Grant
Filed:
June 26, 2019
Date of Patent:
April 23, 2024
Assignees:
KYOWA KIRIN CO., LTD., KAGOSHIMA UNIVERSITY
Inventors:
Nobuaki Takahashi, Ryosuke Nakano, Sayaka Maeda, Yuji Ito
Abstract: The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to the truncated Asp421 epitope of Tau. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody-based molecules of the present invention have particular utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.
Abstract: Methods are disclosed for the reduction or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms using compositions comprising a synergistic combination of thermolysin and at least one aminoglycoside antibacterial agent.
Type:
Grant
Filed:
July 8, 2022
Date of Patent:
April 16, 2024
Assignee:
SMITH & NEPHEW, INC.
Inventors:
Aleksa Jovanovic, Lei Shi, Eric Roche, Paul Renick
Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
April 24, 2023
Date of Patent:
April 9, 2024
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Jens Hukelmann, Heiko Schuster, Lena Wullkopf, Christoph Schraeder, Jens Fritsche, Daniel Johannes Kowalewski, Michael Roemer, Oliver Schoor
Abstract: Disclosed herein are methods for treating cancer by administering to a subject having cancer antibodies against one or more of CD300c, BTN5 (Erythroid membrane-associated protein), TAPBPL (antigen processing (TAP) binding protein like protein), Skint8 (selection and upkeep of intraepithelial T cells 8 protein), and CD300f. Also disclosed herein are methods for treating autoimmune diseases by administering to a subject having an autoimmune disease an IgV domain, or a nucleic acid encoding an IgV domain, from one or more of CD300c, BTN5, TAPBPL, SkintS, and CD300f. Also disclosed herein are antibodies against CD300c and TAPBPL, and fusion proteins that can be used in the methods for treating autoimmune disease.
Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.
Type:
Grant
Filed:
March 3, 2021
Date of Patent:
April 2, 2024
Assignee:
Genzyme Corporation
Inventors:
Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.
Type:
Grant
Filed:
May 29, 2019
Date of Patent:
March 26, 2024
Assignee:
Novartis AG
Inventors:
Michael Didonato, Christoph Erkel, Anna Galkin, Scott Glaser, Klaus Felix Hartlepp, Yong Jia, Alexandra Kraus, Christian Cho-Hua Lee, Sarah Michelle Rue, Jian Shi, Xenia Karola Wezler
Abstract: The present disclosure is directed to human antibodies binding to and neutralizing ebolavirus and methods for use thereof. A further embodiment involves a monoclonal antibody, wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences. In yet another embodiment, there is provided a hybridoma or engineered cell encoding an antibody or antibody fragment. An additional embodiment comprises a vaccine formulation comprising one or more antibodies or antibody fragments characterized by clone-paired heavy and light chain CDR sequences. In still a further embodiment, there is provided a method of protecting the health of a placenta and/or fetus of a pregnant a subject infected with or at risk of infection with ebolavirus comprising delivering to said subject the antibody or antibody fragment.
Type:
Grant
Filed:
July 11, 2019
Date of Patent:
March 26, 2024
Assignees:
VANDERBILT UNIVERSITY, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
James E. Crowe, Jr., Pavlo Gilchuk, Alexander Bukreyev
Abstract: An affinity matured anti-CD22 human monoclonal antibody exhibiting significantly higher affinity (less than 50 pM) compared to the parental antibody (affinity of about 2 nM) is described. The anti-CD22 variant antibody or a fragment thereof, such as a single-chain variable fragment (scFv), can be used as the antigen-binding portion of chimeric antigen receptors (CARs), antibody-drug conjugates (ADCs), immunotoxins or multi-specific antibodies for the treatment of B-cell malignancies.
Type:
Grant
Filed:
July 11, 2019
Date of Patent:
March 26, 2024
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Dimiter S. Dimitrov, Zhongyu Zhu, Sneha Ramakrishna, Terry J. Fry
Abstract: Described herein are compositions composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein.
Type:
Grant
Filed:
December 16, 2021
Date of Patent:
March 19, 2024
Assignee:
MiMedx Group, Inc.
Inventors:
Brenda S. Morse, Somaly Sith, Randall Spencer, Steven Ray, John Daniel, Robert Tofe
Abstract: Described herein are T cells engineered to express a chimeric antigen receptor (CAR), such as an anti-mesothelin CAR alone or in combination with a follicle-stimulating hormone receptor (FSHR) binding domain and/or a dominant negative transforming growth factor-? receptor II (dnTGF?RII) for the treatment of diseases associated with mesothelin expression. Also described are T cells engineered to express a modified T cell receptor (TCR).
Type:
Grant
Filed:
August 29, 2019
Date of Patent:
March 19, 2024
Assignee:
Nanjing Legend Biotech Co., Ltd.
Inventors:
Qing Dai, Jian Liu, Shuai Yang, Kun Jiang, Yuanyuan Peng, Chen Hu, Shu Wu